文献速递瓣膜病与结构性心脏病

人工心脏瓣膜血栓形成

Prosthetic Heart Valve Thrombosis.
PubMed 文献 · J Am Coll Cardiol · 2016-01-01

综述回顾人工心脏瓣膜血栓形成的数据,讨论可能导致瓣膜血栓形成的病理生理机制,并对经导管瓣膜置换时代的启示提供视角。文章区分机械瓣与生物瓣,指出机械瓣置换后需长期抗凝预防血栓栓塞,而生物瓣抗凝价值不确定;经导管生物瓣置换患者术后数月存在血栓栓塞风险,近期数据提示风险此后持续存在。

要点

  • 机械瓣置换后需长期抗凝预防血栓栓塞,生物瓣抗凝价值不确定。
  • 经导管生物瓣置换患者术后数月有血栓栓塞风险,近期数据提示风险持续存在。
  • 生物瓣血栓为后续血栓栓塞提供基础,可能识别可逆的瓣膜功能障碍原因。

核心结论

  • 生物瓣血栓为后续血栓栓塞提供基础,可能识别可逆的瓣膜功能障碍原因。
  • 经导管生物瓣置换患者术后数月存在血栓栓塞风险,近期数据提示风险此后持续存在。

研究设计与样本

  • 综述,回顾人工心脏瓣膜血栓形成的数据,讨论病理生理机制并提供经导管瓣膜置换时代的视角。

主要发现

  • 机械瓣经外科植入,生物瓣可经外科或经导管植入。
  • 机械瓣置换后需长期抗凝预防血栓栓塞,生物瓣抗凝价值不确定。
  • 经导管生物瓣置换患者术后数月有血栓栓塞风险,近期数据提示风险此后持续存在。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although surgery was the mainstay of treatment for valvular heart disease, transcatheter valve therapies have grown exponentially over the past decade. Two types of artificial heart valve exist: mechanical heart valves (MHV), which are implanted surgically, and bioprosthetic heart valves (BHV), which can be implanted via a surgical or transcatheter approach. Whereas long-term anticoagulation is required to prevent thromboembolism after MHV replacement, its value in patients receiving BHVs is uncertain. Patients undergoing transcatheter BHV replacement are at risk for thromboembolism in the first few months, and recent data suggest that the risk continues thereafter. BHV thrombosis provides a substrate for subsequent thromboembolism and may identify a reversible cause of prosthesis dysfunction. Hereafter, the authors: 1) review the data on prosthetic valve thrombosis; 2) discuss the pathophysiological mechanisms that may lead to valve thrombus formation; and 3) provide perspective on the implications of these findings in the era of transcatheter valve replacement.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Dangas GD, Weitz JI, Giustino G, et al. Prosthetic Heart Valve Thrombosis. J Am Coll Cardiol. 2016. PMID: 27978952. doi:10.1016/j.jacc.2016.09.958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。